SCHEMBL2255293

SCHEMBL2255293

CC1(C)Cc2ccccc2NC1(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 3/20 0.40
CREBBP Q92793 2/20 0.40
PGR P06401 1/20 0.39
AR P10275 1/20 0.39
NPC1 O15118 2/20 0.36
KMT2A Q03164 2/20 0.36
AHR P35869 1/20 0.36
PDK2 Q15119 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
HSP90AA1 P07900 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
HK1 P19367 1/20 0.36
MAPK1 P28482 1/20 0.36
RECQL P46063 1/20 0.36
RAB9A P51151 1/20 0.36
GALK1 P51570 1/20 0.36
BLM P54132 1/20 0.36
HKDC1 Q2TB90 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1119036 0.78 GAA (0.46) BRD4CREBBPPGRNPC1KMT2A
SCHEMBL31059284 0.75 HTR5A (0.37) BRD4CREBBPNPC1KMT2AAHR
SCHEMBL23714201 0.75 HTR5A (0.37) BRD4CREBBPNPC1KMT2AAHR
SCHEMBL23352920 0.72 BRD4 (0.35) BRD4CREBBPNPC1KMT2AAHR
SCHEMBL7068997 0.72 KMT2A (0.60) BRD4CREBBPNPC1KMT2AAHR
SCHEMBL30681584 0.71 BRD4 (0.41) BRD4CREBBPNPC1KMT2AAHR
SCHEMBL5837737 0.69 BRD4 (0.42) BRD4CREBBPNPC1KMT2AAHR
SCHEMBL30486500 0.69 KDM4E (0.45) BRD4CREBBPKDM4E
SCHEMBL6773172 0.69 BRD4 (0.42) BRD4CREBBPNPC1KMT2AAHR
SCHEMBL6959929 0.68 BRD4 (0.35) BRD4CREBBPNPC1KMT2AAHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101297077-A Textiles treated with hindered amines MILLIKEN & CO (US) 2008-10-29 CN claimed
WO-2007050245-A2 HINDERED AMINE TREATED TEXTILES MILLIKEN & COMPANY (US) 2007-05-03 WO claimed
US-20070092724-A1 Hindered amine treated textiles MILLIKEN & COMPANY 2007-04-26 US claimed
US-20250354016-A1 HALS AS ANTI-MICROBIAL ADDITIVES IN FREE-RADICAL SYSTEMS ARKEMA FRANCE (FR) 2025-11-20 US disclosed
EP-4536762-A1 HALS AS ANTI-MICROBIAL ADDITIVES IN FREE-RADICAL SYSTEMS ARKEMA FRANCE (FR) 2025-04-16 EP disclosed
WO-2023237771-A1 HALS AS ANTI-MICROBIAL ADDITIVES IN FREE-RADICAL SYSTEMS ARKEMA FRANCE (FR) 2023-12-14 WO disclosed
EP-4289907-A1 HALS AS ANTI-MICROBIAL ADDITIVES IN FREE-RADICAL SYSTEMS ARKEMA FRANCE (FR) 2023-12-13 EP disclosed
US-9249157-B2 Tricyclic heterocycle compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2016-02-02 US disclosed
US-20150246930-A1 TRICYCLIC HETEROCYCLE COMPOUNDS BRISTOL-MEYERS SQUIBB COMPANY (US) 2015-09-03 US disclosed
US-7998886-B2 Hindered amine treated textiles MILLIKEN & COMPANY (US) 2011-08-16 US disclosed
US-7858539-B2 Processes for generating halamine compounds on textile substrates to produce antimicrobial finish MILLIKEN & COMPANY (US) 2010-12-28 US disclosed
CN-101297077-A Textiles treated with hindered amines MILLIKEN & CO (US) 2008-10-29 CN disclosed
US-20080248705-A1 Processes for generating halamine compounds on textile substrates to produce antimicrobial finish MILLIKEN & COMPANY 2008-10-09 US disclosed
US-20070092724-A1 Hindered amine treated textiles MILLIKEN & COMPANY 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150246930-A1 TRICYCLIC HETEROCYCLE COMPOUNDS RCOR3, NR4A3, NCOA3 BRD4 159/4885CREBBP 1187/4885PGR 523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.